The Sabin Vaccine Institute Board of Trustees oversees the activities of the organization and our various programs. We are grateful for the activism and generosity of our Board of Trustees, composed of international leaders in business, civil service, academia and philanthropy.
Axel Hoos, M.D., Ph.D.
Philip K. Russell, M.D.
Peter L. Thoren
H. R. Shepherd, D.Sc.
Dr. Axel Hoos is Senior Vice President, Therapeutic Area (TA) Head for Oncology R&D and Head of Immuno-Oncology at GlaxoSmithKline Pharmaceuticals (GSK). In this role he leads the Oncology TA and builds the immuno-oncology portfolio of GSK across the modalities of antibodies, small molecules, bispecific molecules and cell & gene therapies, for which he directs discovery and development.
In addition to serving as Sabin’s Chairman, Dr. Hoos also serves as Director on the Board of Imugene, a biotech company, Co-Director of the Cancer Immunotherapy Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI).
His efforts in Medicines Development and Global Health focus on novel therapies for life-threatening diseases, scientific and procedural innovation, and broad collaboration across multiple constituents. Through his leadership a new paradigm for the development of cancer immunotherapies has been defined, which helped launch the field of Immuno-Oncology.
Previously, Dr. Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipilimumab), the first life-extending therapy in Immuno-Oncology. Before BMS, Dr. Hoos was Senior Director of Clinical Development at Agenus Bio (previously Antigenics), a biotech company.
Dr. Hoos holds an MD from Ruprecht-Karls-University and a PhD in molecular oncology from the German Cancer Research Center (DKFZ) both in Heidelberg, Germany. He trained in surgery at the Technical University in Munich, Germany and further in surgery, molecular pathology and tumor immunology at Memorial Sloan-Kettering Cancer Center in New York City. He is an alumnus of the Program for Leadership Development at Harvard Business School.
Chief Executive Officer
Amy Finan was appointed as the Chief Executive Officer of the Sabin Vaccine Institute on April 18, 2016.
Prior to joining Sabin, Ms. Finan served as senior vice president responsible for business development at the Biotechnology Innovation Organization (BIO), the world's largest membership organization representing biotechnology companies, academic institutions and state biotechnology centers.
During her 11-year tenure at BIO, Ms. Finan played a critical role in expanding the organization’s membership and revenue base and implementing innovative approaches to fundraising, branding, marketing and programming. In 2011 and simultaneous with her BIO responsibilities, she also served as president of the Biotechnology Institute, an organization founded by BIO in 1998 to promote life science education.
Prior to BIO, Ms. Finan led corporate communications and investor relations for the former clinical-stage biotechnology company EntreMed Inc. Between 1999 and 2001, she created and implemented the biotech initiative of Montgomery County, Maryland, which included economic development policies, incubator programs, legislative packages and communication plans. Ms. Finan began her biotechnology career as a government relations director for the National Association of Biomedical Research.
Ms. Finan studied at the London School of Economics & Political Science and graduated with a bachelor’s degree in political science from Trinity College in Washington, D.C.
Kenneth Kelley is a White House Presidential Executive Fellow, and Senior Advisor to the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Disease Vaccine Research Center (NIAID/VRC), both within the U.S. Department of Health and Human Services (HHS). He is working on special projects within global biosecurity including the U.S. Government's response to the Zika Virus outbreak, aligning vaccine development efforts across agencies throughout the U.S. Government, and engaging with the new global vaccine development fund, the CEPI (Coalition for Epidemic Preparedness Innovations).
Ken has been seconded from his position as a Visiting Scientist in the Department of Health Policy and Management at the Harvard T.H. Chan School of Public Health. Ken is working on the market failure of industry, government and civil society to develop vaccines and drugs against infectious diseases of three types: neglected tropical diseases such as Chikungunya virus, emerging infectious disease threats such as Zika virus, and bioweapons such as engineered Ebola virus. He is also an advisor to the Manage the Microbe Project, a new biosecurity center of scholarship, within the Belfer Center at the Harvard Kennedy School of Government. Ken co-founded PaxVax, a specialty vaccine company, in 2007, and served as its chief executive officer from 2008 to May 2015, where he led the development of Vaxchora (the first new type of vaccine approved by the U.S. FDA in 10 years). He has more than 30 years of entrepreneurial, venture capital, operational and technical biotechnology experience. He selectively serves on the board of directors of private and public biotech companies.
Paul Maddon is a biotechnology entrepreneur and private investor with over 25 years of industry experience. He is the founder of Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), the first biotechnology company to emerge from Columbia University, and he currently serves as the company’s Director and Vice Chairman of the Board of Trustees. During his tenure at Progenics, Paul developed innovative therapeutic products in the fields of gastroenterology, oncology, and infectious diseases. As Chief Science Officer, Paul was responsible for preclinical and clinical development of the Company’s major therapeutic products, including RELISTOR ®. RELISTOR ® was approved in 2008 in the U.S. and E.U. and is now marketed in over 50 countries for the treatment of opioid-induced constipation in patients with advanced illness.
Prior to founding Progenics, from 1981 to 1988, Paul performed research at the Howard Hughes Medical Institute at Columbia University where in a series of landmark studies, he isolated the gene encoding CD4 and demonstrated that CD4 serves as the primary receptor for entry of the AIDS virus (HIV) into immune system. In addition, Paul has a long-standing commitment to science education and to providing research opportunities for students. At Columbia University, Paul received a B.A. in Biochemistry, an M.D. from the College of Physicians and Surgeons and a Ph.D. in Biochemistry and Molecular Biophysics from the Graduate School of Arts and Sciences.
Michael W. Marine, former U.S. Ambassador to the Socialist Republic of Vietnam, served as Chief Executive Officer of the Sabin Vaccine Institute from 2010 to 2016. During his tenure, Ambassador Marine’s leadership was critical to the growth and expansion of the organization and its various programs.
Mr. Marine joined Sabin's leadership team in December 2009 after serving eight months on the Joint Action Committee of the Global Network for Neglected Tropical Diseases, an advocacy and resource mobilization initiative of Sabin.
He was a member of the U.S. State Department’s Foreign Service for 32 years and served as Ambassador to the Socialist Republic of Vietnam from September 2004 to August 2007.
Earlier in his Foreign Service career, Mr. Marine was Deputy Chief of Mission at the U.S. Embassies in Beijing, China, Nairobi, Kenya and Suva, Fiji. He also served in program direction positions in U.S. diplomatic posts in Moscow, Russia, Bonn, Germany and Guangzhou, China.
Mr. Marine enlisted in the U.S. Marine Corps in 1967 and completed his service with the rank of Captain in 1971. He graduated Phi Beta Kappa and summa cum laude from the University of California at Santa Barbara in 1974 with a degree in Asian Studies. He entered the Foreign Service in 1975. He received the State Department’s Superior Honor Award six times.
Regina Rabinovich is the ExxonMobil Malaria Scholar in Residence at Harvard University. She has over 25 years of experience in global health across research, public health and philanthropic sectors, with focus on strategy, global health product development and the introduction and scale-up of tools and strategies resulting in impact on endemic populations.
From 2003-2012, Dr. Rabinovich served as Director of the Infectious Diseases division at the Bill & Melinda Gates Foundation, overseeing the development and implementation of strategies for the prevention, treatment and control of infectious diseases of particular relevance to malaria, pneumonia, diarrhea and neglected infectious diseases. Dr. Rabinovich has served in Chief of the Clinical and Regulatory Affairs Branch at the US National Institute of Allergy and Infectious Diseases (NIAID), focusing on the development and evaluation of vaccines through a network of US clinical research units. She participated in the Children's Vaccine Initiative, a global effort to prevent infectious diseases in children in the developing world.
In 1999, Dr. Rabinovich became director of the PATH Malaria Vaccine Initiative, a project funded by the Bill & Melinda Gates Foundation to advance efforts to develop promising malaria vaccine candidates. She serves on the boards of AERAS, a non-profit biotech focused on development of vaccines for tuberculosis, and the Catholic Medical Mission Board.
Dr. Rabinovich holds a medical degree from Southern Illinois University and a Masters of Public Health degree from the University of North Carolina.
Retired Major General Philip K. Russell, M.D. served in the U.S. Army Medical Corps from 1959 to 1990, pursuing a career in infectious disease and tropical medicine research.
Following his training in internal medicine, he assumed a succession of research assignments at the Walter Reed Army Institute of Research and overseas laboratories in Pakistan, Thailand, and Vietnam. He conducted laboratory and clinical research on a variety of viral and parasitic infectious diseases, including dengue, malaria, hepatitis, and respiratory viruses.
Russell has authored or co-authored more than 100 research publications and contributed to the successful development of several vaccines important to the military and public health, including those of adenovirus, meningitis, and hepatitis A and B. Later, as director of the Walter Reed Army Institute of Research, he led research on vaccines against dengue and malaria. As commander of the U.S. Army Medical Research and Development Command, he spearheaded a major effort to increase the capability of the armed forces to defend against biological agents. His military awards include the legion of Merit and the Distinguished Service Medal.
Following his military service, Russell joined Johns Hopkins University's School of Hygiene and Public Health as professor of international health and worked closely with the World Health Organization as special advisor to the Children's Vaccine Initiative. He was founding board member of the International AIDS Vaccine Initiative. After becoming professor emeritus in 1997, he served as an advisor to the Bill and Melinda Gates Foundation as well as several vaccine programs and was instrumental in creating the Malaria Vaccine Initiative.
Russell has served on numerous advisory boards of national and international agencies, including the Centers for Disease Control, National Institutes of Health and the Institute of Medicine, He served on the Boards of Directors of the International Vaccine Institute and the Aeras Foundation, and continues to be an integral part of the Albert B. Sabin Vaccine Institute. Following the anthrax attacks in 2001, Russell led a Department of Health and Human Services effort to develop and stockpile vaccines and other medical countermeasures against bioterrorism agents. He continues to work on the development of vaccines for the developing world.
Peter L. Thoren is Executive Vice President of Access Industries, Inc., a privately held, U.S.-based industrial group with strategic investments throughout the world. He is involved with numerous organizations focused on foreign policy and economics including The Center for National Policy, The Institute for Strategic Dialogue, the Council on Foreign Relations, and The Economic Club of New York. Before joining Access in 2001, Mr. Thoren held senior management positions with Salomon Inc and practiced law in New York. A native of Washington, D.C., Mr. Thoren received degrees from the University of North Carolina at Chapel Hill, the London School of Economics and Political Science and Georgetown University Law Center.
In Memoriam of Founder and Honorary Trustee
Heloisa Sabin was a founding member of the Sabin Vaccine Institute and served as a trustee or honorary trustee of the Institute from 1993 to 2016. Wife of the late Dr. Albert B. Sabin, Heloisa Sabin dedicated much of her life to continuing the work and legacy of her husband.
An outspoken advocate in the effort to end vaccine preventable diseases, Heloisa shared Dr. Sabin's dedication to the elimination of needless human suffering and poverty. Following her husband's death in 1993, Heloisa joined with Dr. Herman Shepherd, Dr. Robert Chanock and Dr. Philip Russell to found the Sabin Vaccine Institute. She continuously championed the work and legacy of Dr. Sabin by promoting the role of vaccines in eliminating needless deaths from preventable and treatable diseases. Originally from Brazil, Mrs. Sabin lived in Washington, DC, until her death in October of 2016.
In Memoriam of the Founding Chairman
Dr. Shepherd was Founding Chairman of the Sabin Vaccine Institute and served on the Board of Trustees from 1993 to 2010. He also served as the Institute's President for eight years. Until 1993 he was Chairman and CEO of Armstrong Pharmaceuticals, Inc., which he founded as Aerosol Techniques in 1955.
A world-recognized expert on aerosol technologies, Dr. Shepherd spearheaded the development of the metered dose inhaler. He also led a successful effort to fund the nation's first research laboratory dedicated to aerosol pharmaceuticals at Columbia University College of Pharmacy and he is the author of Aerosols: Science and Technology, the first definitive text on the potential of aerosol medications.
Photo by Flickr user francois schnell/CC